Bitget Brings Institutional-Grade Stablecoin Yield to All Users with USDGO, Offering Up to 4.3% APR VICTORIA, Seychelles, May 20, 2026 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), has launched USDGO, GO Uncapped, a passive earning initiative that allows users to earn up to 4.3% APR simply by holding USDGO in their spot […]
VICTORIA, Seychelles, 20 mai 2026 (GLOBE NEWSWIRE) — Bitget, la plus grande bourse universelle (ou UEX, de l’anglais Universal Exchange) au monde, lance USDGO, GO Uncapped, une initiative de gains passifs permettant aux utilisateurs de percevoir un TAEG jusqu’à 4,3 % simplement en détenant des USDGO sur leur compte au comptant ou à terme de la plateforme. […]
The award recognizes Meltwater’s AI-powered innovations that provide actionable intelligence for PR, Communications and Marketing teams SAN FRANCISCO, May 20, 2026 (GLOBE NEWSWIRE) — Meltwater, the global leader in actionable intelligence for PR, Communications and Marketing teams, has been awarded the PRWeek Global Award for Best PR Software or AI Platform, recognizing the company’s leadership in building solutions that turn […]
ALBANY, N.Y., May 19, 2026 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of its upgrade to its two aseptic suites in Valladolid, Spain. The $4 million dollar investment is in accordance with the EU’s GMP Annex 1 standards. The central feature of the […]
ALBANY, N.Y., 19 mai 2026 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), une organisation mondiale de premier plan spécialisée dans la recherche, le développement et la fabrication, a annoncé aujourd’hui l’achèvement de la modernisation de ses deux unités aseptiques à Valladolid, en Espagne. Cet investissement de 4 millions de dollars est conforme aux normes de l’annexe […]
SHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) — Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, patient-accessible therapeutics, today announced the initiation of a Phase 2 clinical study in China of RP902, an oral small-molecule drug developed to address significant unmet medical needs in patients with Alzheimer’s disease. The Phase 2 […]